- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – The Evolving Psychopharmacology Of Major Depressive Disorder

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – The Evolving Psychopharmacology Of Major Depressive Disorder
In this presentation, the objectives are to:
- Provide a brief overview of depression prevalence and current standard treatments
- Review the monoamine hypothesis of depression
- Discuss alternative hypotheses of depression
- Highlight potential new therapeutic intervention targets

Philip G. Janicak, MD
Adjunct Professor and Consultant to the Therapeutic Neuromodulation Program in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine and a Distinguished Life Fellow in the American Psychiatric Association
More

Rachel Self, PhD, MS (OPDC)
Medical Science Director, Neuroscience Field Medical Affairs
More